---
schema_version: "secwatch.filing_event.v1"
accession: "0000805928-25-000010"
form_type: "8-K"
ticker: "AXGN"
cik: "0000805928"
company_name: "Axogen, Inc."
filed_at: "2025-02-25T23:59:59+00:00"
generated_at: "2026-05-26T05:17:14.778321+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Axogen Q4 2024 revenue up 15.1% to $49.4M; reports first quarterly net income of $0.4M

## Summary
- Q4 revenue $49.4M (+15.1% YoY); gross margin 76.1% vs 74.6%.
- Q4 net income $0.4M ($0.01 EPS) vs net loss $3.9M prior year; adjusted net income $3.5M ($0.07 EPS).
- Full-year 2024 revenue $187.3M (+17.8% YoY); adjusted EBITDA $19.8M vs -$1.1M in 2023.
- FDA accepted BLA for Avance Nerve Graft; PDUFA goal date Sept 5, 2025; anticipates approval.
- 2025 guidance: revenue growth 15-17%, gross margin 73-75%, expects positive net cash flow.

## SEC filing metadata
- accession: 0000805928-25-000010
- form_type: 8-K
- ticker: AXGN
- cik: 0000805928
- company_name: Axogen, Inc.
- filed_at: 2025-02-25T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/805928/000080592825000010/0000805928-25-000010-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/805928/000080592825000010/axgn-20250225.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000805928-25-000010
- JSON: https://secwatch.observer/filing/0000805928-25-000010.json
- Plain text: https://secwatch.observer/filing/0000805928-25-000010.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.